Alpelisib

Updated 
August 16, 2019
Reviewed By: 

Alpelisib (Piqray) is a targeted therapyinfo-icon approved by the U.S. Food and Drug Administrationinfo-icon to treat people with advanced or metastaticinfo-icon, hormone receptorinfo-icon-positive breast cancer that has tested positive for a mutationinfo-icon on the PIK3CA geneinfo-icon. It is a PI3K (phosphatidylinositol-3 kinase) inhibitor,  a type of medicineinfo-icon that works by blocking a pathway in cancer cells, called PI3K, that may cause breast cancers to stop responding to hormonal therapies. It is given with the hormonal therapyinfo-icon fulvestrantinfo-icon (Faslodexinfo-icon).

Alpelisib was approved by the FDAinfo-icon in May 2019 and is the first PI3K inhibitor approved to treat breast cancer. 

How Alpelisib Works

A mutationinfo-icon on the PIK3CA geneinfo-icon can cause the PI3K pathway in breast cancer cells to become too active. Researchers believe this path causes some breast cancer to stop responding to hormonal therapyinfo-icon. Alpelisib is a PI3K inhibitor, meaning it blocks this pathway and works with hormonal therapy to keep the cancer from growing.

Who Gets Alpelisib

Alpelisib is approved for people with advanced or metastaticinfo-icon, hormone receptorinfo-icon-positive, HER2-negative breast cancer that has grown during or after treatment with hormonal therapyinfo-icon. The tumorinfo-icon must also test positive for a mutationinfo-icon on the PIK3CA geneinfo-icon. This mutation is present in the tumors of about 40 percent of people with this diagnosisinfo-icon. Along with alpelisib, the FDAinfo-icon approved a biomarker test, the therascreenPIK3CA RGQ PCR kit, to test for this mutation.

How Alpelisib is given

Alpelisib is a pill. The standard doseinfo-icon is two 150 milligram tablets each day. It is given along with fulvestrantinfo-icon, which is given as a shot. Fulvestrant is given three times the first month, then once a month after that.

Side Effects and Things to Remember

High blood sugar is a notable side effectinfo-icon of alpelisib. In the SOLAR-1 trial it was the most common reason people stopped treatment with alpelisib. It can be managed with diabetes medicines, changes in diet, changes to the doseinfo-icon of alpelisib, and taking a break from alpelisib.

Other common side effects were

Tell your doctor if you are pregnant or planning to become pregnant. Alpelisib may be dangerous to a fetus so it is recommended that you not take this medicineinfo-icon while pregnant and not get pregnant for at least a week after you have stopped treatment.

Alpelisib can also cause some serious but rare conditions including lung inflammationinfo-icon, allergic reactions, and severe skin reactions. Let your doctor know if you have had any serious skin reactions to medicines in the past.

You must have Javascript enabled to use this form.

More In Hormone Receptor-Positive